arrow
M

Morten H. Bestle

University of Copenhagen
H指数:36
被引数:7,691

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Continuous Versus Intermittent Glucose Monitoring in Intensive Care Unit Patients: A Systematic Review With Meta-Analysis

连续与间歇性葡萄糖监测在重症监护病房患者中的效果:一项系统评价与Meta分析

2026-03-300
PRE
Hyperglycemia and insulin use in patients with COVID-19 and severe hypoxemia allocated to 12 mg vs. 6 mg of dexamethasone: a secondary analysis of the COVID STEROID 2 randomized trial

高血糖和胰岛素使用在COVID-19合并严重低氧血症患者中分配接受12 mg与6 mg地塞米松的情况:COVID STEROID 2随机试验的二次分析

2025-07-150
OAAI
Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy A Randomized Clinical Trial

成人脓毒症休克和内皮病变的伊洛前列素和器官功能障碍的随机临床试验

2024-09-111
OAAI
Long-term mortality and health-related quality of life with lower versus higher oxygenation targets in intensive care unit patients with COVID-19 and severe hypoxaemia

新型冠状病毒肺炎和严重低氧血症重症监护病房患者的长期死亡率和健康相关生活质量,较低或较高氧合目标

2024-09-051
OAAI
Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19

新型冠状病毒肺炎中较低与较高的氧合目标和没有生命支持的日子

2024-04-0915
OA
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
2024-03-040
OAAI
Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium

氟哌啶醇与安慰剂在急性入院的成年ICU谵妄患者中的长期结果

2024-01-037
OAAI
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)

重组人碱性磷酸酶治疗脓毒症相关急性肾损伤 (REVIVAL) 的3期临床试验

2024-01-0317
OAAI
Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU) (vol 49, pg 1327, 2023)

ICU患者的血小板减少症和血小板输注: 一项国际初始队列研究 (PLOT-ICU) (第49卷,1327页,2023)

2023-12-110
OAAI
Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)

ICU患者的血小板减少症和血小板输注: 一项国际初始队列研究 (PLOT-ICU)

2023-10-0914
OAAI
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, aTREM-1 inhibitor, in patients with septic shock (ASTONISH) : a double-blind, randomised, controlled, phase 2b trial

aTREM-1抑制剂nangibotide在脓毒症休克患者中的疗效,安全性和最佳生物标志物富集策略的前瞻性评估 (ASTONISH): 一项双盲,随机,对照,2b期试验

2023-10-0119
OAAI